PT3448848T - Forma polimórfica de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil)etil]-2h-indazol-5-il}-6-(trifluorometil)piridina-2-carboxamida - Google Patents

Forma polimórfica de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil)etil]-2h-indazol-5-il}-6-(trifluorometil)piridina-2-carboxamida

Info

Publication number: PT3448848T
Authority: PT; Portugal
Prior art keywords: methylsulphonyl; hydroxypropan; indazol; carboxamide; trifluoromethyl
Prior art date: 2016-04-29

Application number

PT177185600T

Other languages

English (en)

Original Assignee

Bayer Pharma AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-04-29

Filing date

2017-04-25

Publication date

2024-01-02

2017-04-25 Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG

2024-01-02 Publication of PT3448848T publication Critical patent/PT3448848T/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/86—Hydrazides; Thio or imino analogues thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Obesity (AREA)
Hematology (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Reproductive Health (AREA)
Ophthalmology & Optometry (AREA)
Orthopedic Medicine & Surgery (AREA)
Gastroenterology & Hepatology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)

PT177185600T 2016-04-29 2017-04-25 Forma polimórfica de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil)etil]-2h-indazol-5-il}-6-(trifluorometil)piridina-2-carboxamida PT3448848T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP16167652		2016-04-29

Publications (1)

Publication Number	Publication Date
PT3448848T true PT3448848T (pt)	2024-01-02

Family

ID=55860769

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT177185584T PT3448846T (pt)	2016-04-29	2017-04-25	Síntese de indazóis
PT177185600T PT3448848T (pt)	2016-04-29	2017-04-25	Forma polimórfica de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil)etil]-2h-indazol-5-il}-6-(trifluorometil)piridina-2-carboxamida

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PT177185584T PT3448846T (pt)	2016-04-29	2017-04-25	Síntese de indazóis

Country Status (42)

Country	Link
US (2)	US10501417B2 (pt)
EP (4)	EP4275755A3 (pt)
JP (2)	JP7068188B2 (pt)
KR (2)	KR102373220B1 (pt)
CN (3)	CN109071489B (pt)
AR (1)	AR108245A1 (pt)
AU (2)	AU2017257211B2 (pt)
CA (1)	CA3022324C (pt)
CL (2)	CL2018003087A1 (pt)
CO (2)	CO2018011622A2 (pt)
CU (1)	CU20180131A7 (pt)
DK (2)	DK3448848T3 (pt)
DO (1)	DOP2018000237A (pt)
EA (2)	EA201892415A1 (pt)
EC (1)	ECSP18081437A (pt)
ES (2)	ES2883298T3 (pt)
FI (1)	FI3448848T3 (pt)
GE (1)	GEP20217214B (pt)
HR (2)	HRP20231454T1 (pt)
HU (2)	HUE064389T2 (pt)
IL (2)	IL262414B2 (pt)
JO (2)	JOP20170100B1 (pt)
LT (2)	LT3448848T (pt)
MA (1)	MA44759B1 (pt)
MX (2)	MX383591B (pt)
MY (2)	MY187184A (pt)
NI (1)	NI201800112A (pt)
PE (1)	PE20190107A1 (pt)
PH (1)	PH12018502289B1 (pt)
PL (2)	PL3448846T3 (pt)
PT (2)	PT3448846T (pt)
RS (2)	RS62112B1 (pt)
SA (1)	SA518400333B1 (pt)
SG (2)	SG11201808108XA (pt)
SI (2)	SI3448848T1 (pt)
SV (1)	SV2018005775A (pt)
TN (1)	TN2018000352A1 (pt)
TW (2)	TWI657084B (pt)
UA (2)	UA124103C2 (pt)
UY (2)	UY37215A (pt)
WO (2)	WO2017186689A1 (pt)
ZA (1)	ZA201808057B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO3705B1 (ar)	2014-11-26	2021-01-31	Bayer Pharma AG	إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
WO2017148902A1 (de)	2016-03-03	2017-09-08	Bayer Pharma Aktiengesellschaft	Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
PL3448846T3 (pl) *	2016-04-29	2021-12-20	Bayer Pharma Aktiengesellschaft	Synteza indazoli
HUE049331T2 (hu)	2016-04-29	2020-09-28	Bayer Pharma AG	Indazolok szintézise
RU2743170C2 (ru)	2016-06-01	2021-02-15	Байер Энимал Хелс Гмбх	Замещенные индазолы, пригодные для лечения и предупреждения аллергических и/или воспалительных заболеваний у животных
CN109152771B (zh)	2016-06-01	2022-07-19	拜耳医药股份有限公司	2-取代的吲唑用于治疗和预防自身免疫疾病的用途
JOP20180011A1 (ar)	2017-02-16	2019-01-30	Gilead Sciences Inc	مشتقات بيرولو [1، 2-b]بيريدازين
DK3816164T5 (da)	2018-06-25	2024-07-22	Chia Tai Tianqing Pharmaceutical Group Co Ltd	Isothiazolo[5,4-d]pyrimidin-forbindelse som irak4-inhibitor
TWI721483B (zh)	2018-07-13	2021-03-11	美商基利科學股份有限公司	吡咯并[1,2-b]嗒𠯤衍生物
CN110981903A (zh) *	2019-11-28	2020-04-10	南京正济医药研究有限公司	一种艾日布林中间体化合物提高光学纯度的精制方法
WO2022072718A1 (en)	2020-09-30	2022-04-07	Nobell Foods, Inc.	Recombinant milk proteins and food compositions comprising the same
US10947552B1 (en)	2020-09-30	2021-03-16	Alpine Roads, Inc.	Recombinant fusion proteins for producing milk proteins in plants
US10894812B1 (en)	2020-09-30	2021-01-19	Alpine Roads, Inc.	Recombinant milk proteins
CN114469979B (zh) *	2021-12-15	2024-04-09	安徽贝克生物制药有限公司	一种核糖核苷类似物的药物组合物、吸入剂及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7163937B2 (en)	2003-08-21	2007-01-16	Bristol-Myers Squibb Company	Cyclic derivatives as modulators of chemokine receptor activity
BRPI0707718A2 (pt)	2006-02-10	2011-05-10	Summit Corp Plc	uso de um composto
US7879887B2 (en)	2006-06-29	2011-02-01	Nissan Chemical Industries, Ltd.	α-amino acid derivatives and medicaments containing the same as an active ingredient
EP2061786A2 (en)	2006-09-07	2009-05-27	Biogen Idec MA Inc.	Indazole derivatives as modulators of interleukin-1 receptor-associated kinase
EP2486925A4 (en)	2009-10-09	2014-03-19	Mitsubishi Tanabe Pharma Corp	Therapeutic agent for cerebral infarction
WO2011153588A1 (en)	2010-06-10	2011-12-15	Biota Scientific Management Pty Ltd	Viral polymerase inhibitors
EP2655357B1 (en)	2010-12-20	2016-06-22	Merck Serono S.A.	Indazolyl triazole derivatives as irak inhibitors
WO2013106254A1 (en)	2012-01-11	2013-07-18	Dow Agrosciences Llc	Pesticidal compositions and processes related thereto
US9126984B2 (en) *	2013-11-08	2015-09-08	Iteos Therapeutics	4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
EP3066090A1 (en) *	2013-11-08	2016-09-14	iTeos Therapeutics	4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
TWI667233B (zh) *	2013-12-19	2019-08-01	德商拜耳製藥公司	新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
HK1231480A1 (zh) *	2014-01-10	2017-12-22	Aurigene Discovery Technologies Limited	作为irak4抑制剂的吲唑化合物
JO3705B1 (ar)	2014-11-26	2021-01-31	Bayer Pharma AG	إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
WO2016174183A1 (en)	2015-04-30	2016-11-03	Bayer Pharma Aktiengesellschaft	Combinations of inhibitors of irak4 with inhibitors of btk
CA2992406A1 (en)	2015-07-15	2017-01-19	Aurigene Discovery Technologies Limited	Indazole and azaindazole compounds as irak-4 inhibitors
WO2017148902A1 (de)	2016-03-03	2017-09-08	Bayer Pharma Aktiengesellschaft	Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
EP3219329A1 (en) *	2016-03-17	2017-09-20	Bayer Pharma Aktiengesellschaft	Combinations of copanlisib
HUE049331T2 (hu)	2016-04-29	2020-09-28	Bayer Pharma AG	Indazolok szintézise
PL3448846T3 (pl) *	2016-04-29	2021-12-20	Bayer Pharma Aktiengesellschaft	Synteza indazoli
RU2743170C2 (ru)	2016-06-01	2021-02-15	Байер Энимал Хелс Гмбх	Замещенные индазолы, пригодные для лечения и предупреждения аллергических и/или воспалительных заболеваний у животных
CN109152771B (zh)	2016-06-01	2022-07-19	拜耳医药股份有限公司	2-取代的吲唑用于治疗和预防自身免疫疾病的用途

2017
- 2017-04-25 PL PL17718558T patent/PL3448846T3/pl unknown
- 2017-04-25 EP EP23189520.2A patent/EP4275755A3/en not_active Withdrawn
- 2017-04-25 MA MA44759A patent/MA44759B1/fr unknown
- 2017-04-25 AU AU2017257211A patent/AU2017257211B2/en active Active
- 2017-04-25 UA UAA201811516A patent/UA124103C2/uk unknown
- 2017-04-25 SG SG11201808108XA patent/SG11201808108XA/en unknown
- 2017-04-25 EP EP17718558.4A patent/EP3448846B1/en active Active
- 2017-04-25 WO PCT/EP2017/059744 patent/WO2017186689A1/en not_active Ceased
- 2017-04-25 MY MYPI2018703968A patent/MY187184A/en unknown
- 2017-04-25 SI SI201731443T patent/SI3448848T1/sl unknown
- 2017-04-25 UA UAA201811329A patent/UA123169C2/uk unknown
- 2017-04-25 HU HUE17718560A patent/HUE064389T2/hu unknown
- 2017-04-25 PT PT177185584T patent/PT3448846T/pt unknown
- 2017-04-25 EP EP17718560.0A patent/EP3448848B1/en active Active
- 2017-04-25 HU HUE17718558A patent/HUE056460T2/hu unknown
- 2017-04-25 CN CN201780026130.4A patent/CN109071489B/zh active Active
- 2017-04-25 US US16/097,065 patent/US10501417B2/en active Active
- 2017-04-25 ES ES17718558T patent/ES2883298T3/es active Active
- 2017-04-25 MX MX2018013235A patent/MX383591B/es unknown
- 2017-04-25 PT PT177185600T patent/PT3448848T/pt unknown
- 2017-04-25 HR HRP20231454TT patent/HRP20231454T1/hr unknown
- 2017-04-25 JP JP2018556409A patent/JP7068188B2/ja active Active
- 2017-04-25 JP JP2018556408A patent/JP6954924B2/ja active Active
- 2017-04-25 DK DK17718560.0T patent/DK3448848T3/da active
- 2017-04-25 EA EA201892415A patent/EA201892415A1/ru unknown
- 2017-04-25 EP EP23189176.3A patent/EP4275754A3/en not_active Ceased
- 2017-04-25 LT LTEPPCT/EP2017/059767T patent/LT3448848T/lt unknown
- 2017-04-25 GE GEAP201714933A patent/GEP20217214B/en unknown
- 2017-04-25 RS RS20210898A patent/RS62112B1/sr unknown
- 2017-04-25 ES ES17718560T patent/ES2966772T3/es active Active
- 2017-04-25 LT LTEP17718558.4T patent/LT3448846T/lt unknown
- 2017-04-25 SG SG11201808566WA patent/SG11201808566WA/en unknown
- 2017-04-25 HR HRP20211072TT patent/HRP20211072T1/hr unknown
- 2017-04-25 WO PCT/EP2017/059767 patent/WO2017186703A1/en not_active Ceased
- 2017-04-25 TN TNP/2018/000352A patent/TN2018000352A1/en unknown
- 2017-04-25 DK DK17718558.4T patent/DK3448846T3/da active
- 2017-04-25 RS RS20231171A patent/RS64928B1/sr unknown
- 2017-04-25 CA CA3022324A patent/CA3022324C/en active Active
- 2017-04-25 PL PL17718560.0T patent/PL3448848T3/pl unknown
- 2017-04-25 AU AU2017256626A patent/AU2017256626B2/en active Active
- 2017-04-25 PE PE2018002251A patent/PE20190107A1/es unknown
- 2017-04-25 KR KR1020187030698A patent/KR102373220B1/ko not_active Expired - Fee Related
- 2017-04-25 MX MX2018013234A patent/MX380032B/es unknown
- 2017-04-25 KR KR1020187030699A patent/KR102373017B1/ko not_active Expired - Fee Related
- 2017-04-25 EA EA201892430A patent/EA038035B1/ru unknown
- 2017-04-25 CN CN201780040919.5A patent/CN109415340B/zh active Active
- 2017-04-25 IL IL262414A patent/IL262414B2/en unknown
- 2017-04-25 US US16/097,067 patent/US10759758B2/en active Active
- 2017-04-25 FI FIEP17718560.0T patent/FI3448848T3/fi active
- 2017-04-25 CU CU2018000131A patent/CU20180131A7/es unknown
- 2017-04-25 SI SI201730851T patent/SI3448846T1/sl unknown
- 2017-04-25 MY MYPI2018703965A patent/MY190319A/en unknown
- 2017-04-25 CN CN202110343286.3A patent/CN113185457A/zh active Pending
- 2017-04-27 JO JOP/2017/0100A patent/JOP20170100B1/ar active
- 2017-04-27 JO JOP/2017/0099A patent/JOP20170099B1/ar active
- 2017-04-28 TW TW106114178A patent/TWI657084B/zh not_active IP Right Cessation
- 2017-04-28 TW TW106114180A patent/TWI649314B/zh active
- 2017-04-28 UY UY0001037215A patent/UY37215A/es not_active Application Discontinuation
- 2017-04-28 AR ARP170101088A patent/AR108245A1/es unknown
- 2017-04-28 UY UY0001037216A patent/UY37216A/es active IP Right Grant
2018
- 2018-10-26 PH PH12018502289A patent/PH12018502289B1/en unknown
- 2018-10-29 CL CL2018003087A patent/CL2018003087A1/es unknown
- 2018-10-29 EC ECSENADI201881437A patent/ECSP18081437A/es unknown
- 2018-10-29 CO CONC2018/0011622A patent/CO2018011622A2/es unknown
- 2018-10-29 CL CL2018003088A patent/CL2018003088A1/es unknown
- 2018-10-29 SA SA518400333A patent/SA518400333B1/ar unknown
- 2018-10-29 CO CONC2018/0011644A patent/CO2018011644A2/es unknown
- 2018-10-29 DO DO2018000237A patent/DOP2018000237A/es unknown
- 2018-10-29 SV SV2018005775A patent/SV2018005775A/es unknown
- 2018-10-29 IL IL262659A patent/IL262659B/en active IP Right Grant
- 2018-10-29 NI NI201800112A patent/NI201800112A/es unknown
- 2018-11-28 ZA ZA2018/08057A patent/ZA201808057B/en unknown

Also Published As

Publication number	Publication date
DK3448848T3 (da)	2023-12-18
JP2019514922A (ja)	2019-06-06
SI3448848T1 (sl)	2024-01-31
IL262414B2 (en)	2023-10-01
GEP20217214B (en)	2021-01-25
WO2017186689A1 (en)	2017-11-02
UA123169C2 (uk)	2021-02-24
AU2017256626A1 (en)	2018-10-11
DOP2018000237A (es)	2018-11-15
JP7068188B2 (ja)	2022-05-16
PH12018502289A1 (en)	2019-07-15
KR102373017B1 (ko)	2022-03-11
JP2019514923A (ja)	2019-06-06
SA518400333B1 (ar)	2022-06-05
CL2018003088A1 (es)	2019-01-25
HRP20211072T1 (hr)	2021-10-01
UY37216A (es)	2018-06-29
NI201800112A (es)	2019-08-29
SG11201808108XA (en)	2018-10-30
LT3448848T (lt)	2023-11-27
EP4275755A3 (en)	2023-12-27
EP3448848A1 (en)	2019-03-06
MX383591B (es)	2025-03-14
EA038035B1 (ru)	2021-06-25
PL3448846T3 (pl)	2021-12-20
JP6954924B2 (ja)	2021-10-27
TW201738230A (zh)	2017-11-01
CO2018011622A2 (es)	2018-11-22
FI3448848T3 (fi)	2023-12-21
US10501417B2 (en)	2019-12-10
CA3022324A1 (en)	2017-11-02
UY37215A (es)	2017-11-30
HRP20231454T1 (hr)	2024-03-01
CA3022332A1 (en)	2017-11-02
EP3448848B1 (en)	2023-09-27
EP4275755A2 (en)	2023-11-15
ES2883298T3 (es)	2021-12-07
IL262659B (en)	2021-05-31
MY187184A (en)	2021-09-09
MA44759A (fr)	2019-03-06
CN113185457A (zh)	2021-07-30
AR108245A1 (es)	2018-08-01
CN109071489B (zh)	2020-07-10
CU20180131A7 (es)	2019-06-04
BR112018072246A2 (pt)	2019-02-12
TW201738232A (zh)	2017-11-01
DK3448846T3 (da)	2021-08-16
BR112018072242A2 (pt)	2019-04-09
PE20190107A1 (es)	2019-01-15
PT3448846T (pt)	2021-08-19
TWI657084B (zh)	2019-04-21
US10759758B2 (en)	2020-09-01
AU2017257211B2 (en)	2021-05-27
KR20180137497A (ko)	2018-12-27
SV2018005775A (es)	2019-02-07
SG11201808566WA (en)	2018-11-29
KR102373220B1 (ko)	2022-03-11
EP3448846A1 (en)	2019-03-06
NZ746526A (en)	2023-08-25
WO2017186703A1 (en)	2017-11-02
IL262659A (en)	2018-12-31
US20190106407A1 (en)	2019-04-11
HUE064389T2 (hu)	2024-03-28
IL262414B1 (en)	2023-06-01
ZA201808057B (en)	2023-05-31
LT3448846T (lt)	2021-07-26
ECSP18081437A (es)	2018-11-30
EP4275754A2 (en)	2023-11-15
MX380032B (es)	2025-03-11
JOP20170100B1 (ar)	2022-03-14
ES2966772T3 (es)	2024-04-24
CO2018011644A2 (es)	2018-11-13
MY190319A (en)	2022-04-13
CN109415340B (zh)	2021-10-12
KR20180137496A (ko)	2018-12-27
PL3448848T3 (pl)	2024-03-11
PH12018502289B1 (en)	2022-04-06
RS64928B1 (sr)	2023-12-29
MA44759B1 (fr)	2024-01-31
EP3448846B1 (en)	2021-05-26
JOP20170099B1 (ar)	2022-03-14
UA124103C2 (uk)	2021-07-21
AU2017256626B2 (en)	2021-05-27
HUE056460T2 (hu)	2022-02-28
IL262414A (en)	2018-12-31
CN109415340A (zh)	2019-03-01
TN2018000352A1 (en)	2020-06-15
SI3448846T1 (sl)	2021-09-30
MX2018013234A (es)	2019-02-13
RS62112B1 (sr)	2021-08-31
EA201892430A1 (ru)	2019-05-31
CA3022324C (en)	2024-10-29
MX2018013235A (es)	2019-02-13
EP4275754A3 (en)	2023-12-27
NZ746469A (en)	2023-08-25
AU2017257211A1 (en)	2018-10-11
TWI649314B (zh)	2019-02-01
US20190112270A1 (en)	2019-04-18
CL2018003087A1 (es)	2019-02-22
EA201892415A1 (ru)	2019-05-31
CN109071489A (zh)	2018-12-21

Publication	Publication Date	Title
IL262414A (en)	2018-12-31	A polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulfonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
IL249491A0 (en)	2017-02-28	Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidin-4- Carboxamide
IL253060A0 (en)	2017-08-31	Pyrimidine compounds are fused to treat hiv
IL266955B1 (en)	2023-05-01	Polymorphs of spiafatrin and its salts
PL3297631T3 (pl)	2020-03-31	Antagoniści receptora NK-1/NK-3 do leczenia uderzeń gorąca
LT3183254T (lt)	2019-08-26	Naujieji spiro[3h-indol-3,2' -pirolidin]-2(1h)-ono junginiai ir dariniai, kaip mdm2-p53 inhibitoriai
IL262391B (en)	2022-03-01	Crystal forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-h2-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide
ZA201803748B (en)	2019-03-27	4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-oxoethyl) pyridin-3-yl)oxy)benzonitrile and processes of preparation
DK3432872T3 (da)	2021-10-11	Eflornithin til anvendelse til behandling af temozolomid tilbagevendende/refraktær anaplastisk astrocytom
IL284081A (en)	2021-07-29	Somatostatin receptor antagonist compounds and methods of using the same
SG11201704431VA (en)	2017-09-28	Novel salt of fused pyrimidine compound and crystal thereof
IL255889A (en)	2018-04-30	Melting method of silicon using the float-zone melting
HK1231069A1 (en)	2017-12-15	Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
HK40015980A (en)	2020-09-04	Polymorphs of sepiapterin and salts thereof